Keep up to date on the latest MS and COVID-19 data

July 14, 2020

Multiple Sclerosis specialists and organisations provided guidance for people with Multiple Sclerosis as it relates to COVID-19. These research articles, case studies and letters include advice for those on immunosuppressives, based on the theoretical understandings of MS and the mechanisms of the treatments.

Click below for more information:

  • COVID-19 in persons with multiple sclerosis treated with ocrelizumab – A pharmacovigilance case series.
    Written by: Richard Hughes, Rosetta Pedotti, and Harold Koendgen
    Read full text
  • The underpinning biology relating to multiple sclerosis disease-modifying treatments during the COVID-19 pandemic.
    Written by: David Baker, Sandra Amor, Angray S. Kang,  Klaus Schmierer, Gavin Giovannoni.
    Read full text or download here.
  • An Italian programme for COVID-19 infection in multiple sclerosis.
    Written by: Maria Pia Sormani, on behalf of the Italian Study Group on COVID-19 infection in multiple sclerosis.
    Read full text at: The Lancet | Science Direct
  • Patients with MS treated with immunosuppressive agents: Across the COVID-19 spectrum
    Written by: C. Louapre, E. Maillart, T. Roux, V. Pourcher, G. Bussone, C. Lubetzki, C. Papeix
    Read full text
  • COVID-19 pandemic: The experience of a multiple sclerosis centre in Chile
    Written by: Ethel Ciampi, Reinaldo Uribe-San-Martin, Claudia Cárcamo
    Read full text
  • Immunosuppression during the COVID-19 pandemic in neuromyelitis optica spectrum disorders patients: A new challenge
    Written by: Edgar Carnero Contentti, Jorge Correa
    Read full text
  • Mild COVID-19 infection despite chronic B cell depletion in a patient with aquaporin-4-positive neuromyelitis Optica spectrum disorder
    Written by: Marina A. Creed, Enrique Ballesteros, L. John Greenfield Jr., Jaime Imitola
    Read full text

For more information, consider following Gavin Giovannoni’s coverage of MS and COVID-19 in his blog. Consider reading his summary of the biology of MS and COVID-19


Back to top